ArticleJTCVS open2026
The impact of thoracic aortic endograft explant on open descending and thoracoabdominal aortic replacement.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Thoracic endovascular aortic repair (TEVAR) has become the primary treatment for descending thoracic aortic aneurysms and complicated acute type B aortic dissections. Consequently, a significant cohort of patients experience endograft failure or infection requiring open surgical explant. This study evaluated the impact of TEVAR explant on open descending (DTA) or thoracoabdominal aortic (TAA) replacement. Methods: Between January 2006 and January 2025, 442 adult patients underwent open DTA or TAAA repair at a single institution, among whom 68 patients (15%) had a previous TEVAR and underwent TEVAR explant (EXPLANT) at time of surgery. Results: Fifty-seven percent of patients underwent DTA and 43% underwent TAA replacement. Open DTA or TAA replacement occurred a median of 0.9 (0.3, 2.4) years after TEVAR. Indications for surgery included expanding aneurysm secondary to endoleak (75%) and graft infection (25%). Circulation management (left heart bypass or hypothermic circulatory arrest) was similar between EXPLANT and no EXPLANT groups. There was no difference in postoperative outcomes between EXPLANT and no EXPLANT groups including stroke (7.4% vs 5.6%) and paraplegia (10% vs 8.6%). Overall operative mortality was 19% and was similar between groups. TEVAR EXPLANT was not a risk factor for mortality (odds ratio, 1.14; Conclusions: TEVAR explant for aneurysm expansion does not impact outcomes after open DTA or TAA aneurysm repair. However, explant of infected thoracic endografts typically requires circulatory arrest and is associated with increased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.